### Guideline Page and Request

**MDS-3, -4, and -6**

**Internal request:**
Based on the recent FDA approval, consider inclusion of oral decitabine and cedazuridine (DEC-C) for the treatment of adult patients with MDS, including previously treated and untreated, *de novo* and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and CMML) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

**External request:**
Submission from Taiho Oncology Inc., request to include oral DEC-C in the guidelines for International Prognostic Scoring Systems Revised (IPSS-R and IPSS) and World Health Organization Classification-based Prognostic Scoring System (WPSS) in adult patients for previously treated and untreated, *de novo* and secondary MDS and CMML.

### Panel Discussion/References

Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include the following footnote: *Oral decitabine and cedazuridine (DEC-C) could be considered as a substitution for intravenous decitabine (Garcia-Manero G, et al. Blood 2020;136:674-683).*

### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>1</td>
<td>2</td>
<td>7</td>
</tr>
</tbody>
</table>